sorafenib has been researched along with ubenimex in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ubenimex) | Trials (ubenimex) | Recent Studies (post-2010) (ubenimex) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 930 | 43 | 182 |
| Protein | Taxonomy | sorafenib (IC50) | ubenimex (IC50) |
|---|---|---|---|
| Aminopeptidase B | Rattus norvegicus (Norway rat) | 6 | |
| M1 family aminopeptidase | Plasmodium falciparum FcB1/Columbia | 0.284 | |
| Cytosol aminopeptidase | Bos taurus (cattle) | 1.0005 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 6.45 | |
| Leukotriene A-4 hydrolase | Homo sapiens (human) | 1.4742 | |
| Aminopeptidase N | Homo sapiens (human) | 2.6333 | |
| Aminopeptidase N | Sus scrofa (pig) | 3.8211 | |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | 2.7 | |
| Puromycin-sensitive aminopeptidase | Homo sapiens (human) | 3.5 | |
| Bacterial leucyl aminopeptidase | Vibrio proteolyticus | 1.0005 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Ogawa, H; Umeshita, K; Wada, H; Yamada, D; Yamashita, M | 1 |
| Ding, S; Gao, D; Gao, M; Liu, S; Lv, J; Niu, Z; Wang, X; Wang, Z | 1 |
3 other study(ies) available for sorafenib and ubenimex
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 Antigens; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leucine; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib | 2016 |
Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
Topics: Adenine; Animals; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Leucine; Lipid Metabolism; Mice; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |